US$ 25.36
glp 1 pathophysiology Mechanisms by which GLP-1 agonists may exert beneficial effects on the GLP-1a: Going beyond Traditional Use
Description
Biessels GJ, Reagan LP

[5] Byetta (exenatide) [prescribing information]

Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study

The FDA has raised concerns about the increased risk of dosing errors, improper storage and fraudulently labeled GLP-1s from compounding pharmacies

An open question remains whether chronic use of GLP1RAs will result in tachyphylaxis of the gastric slowing effect, which will mitigate the risk of DDI [51,52,53]
